Phase 2 ALK Clinical Trials
20 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 20 trials
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
ALK-Positive Lung CancerALK-positive Non-small Cell Lung CancerALK-positive NSCLC
TRIANA Biomedicines, Inc.160 enrolled9 locationsNCT07491497
Recruiting
Phase 1Phase 2
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
ALK Fusion-positive Solid or CNS Tumors
Hoffmann-La Roche42 enrolled33 locationsNCT04774718
Recruiting
Phase 2
Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
Anaplastic Large Cell Lymphoma, ALK-Positive
New York Medical College20 enrolled1 locationNCT07013565
Recruiting
Phase 2
Fisetin to Reduce Senescence and Mobility Impairment in PAD
ClaudicationPeripheral Arterial DiseaseAging+2 more
Northwestern University34 enrolled1 locationNCT06399809
Recruiting
Phase 1Phase 2
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Colorectal, CancerHepatocellular CarcinomaMelanoma+15 more
7 Hills Pharma, LLC126 enrolled5 locationsNCT06362369
Recruiting
Phase 1Phase 2
Alectinib Pharmacokinetic in Patients With NSCLC
ALK Gene MutationNon-small Cell Lung Cancer Stage IIIB
Instituto Nacional de Cancerologia de Mexico45 enrolled1 locationNCT05713006
Recruiting
Phase 2
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
Recurrent Grade 3b Follicular LymphomaRefractory Grade 3b Follicular LymphomaRecurrent Transformed Non-Hodgkin Lymphoma+28 more
Mayo Clinic41 enrolled7 locationsNCT06834373
Recruiting
Phase 1Phase 2
Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
Anaplastic Large Cell Lymphoma, ALK-PositiveInflammatory Myofibroblastic TumorOther Solid Tumor
Princess Maxima Center for Pediatric Oncology65 enrolled2 locationsNCT04925609
Recruiting
Phase 1Phase 2
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
NSCLC Stage IVALK Fusion Protein Expression
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins12 enrolled1 locationNCT05950139
Recruiting
Phase 2
A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases
NSCLC Stage IV Without EGFR/ALK Mutation
Xinqiao Hospital of Chongqing427 enrolled1 locationNCT06947694
Recruiting
Phase 2
Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases
NSCLC Stage IV Without EGFR/ALK Mutation
Xinqiao Hospital of Chongqing366 enrolled1 locationNCT06953843
Recruiting
Phase 2
Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury
Central Nervous System DiseasesGenital Diseases, MaleHypogonadism+17 more
North Florida Foundation for Research and Education21 enrolled2 locationsNCT04460872
Recruiting
Phase 2
Passive Stretching in Peripheral Arterial Disease Patients
Peripheral Arterial DiseaseInflammationWalking, Difficulty
University of Wisconsin, La Crosse64 enrolled1 locationNCT06420752
Recruiting
Phase 2
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
Non-small Cell Lung CancerALK Gene MutationEGFR Gene Mutation+2 more
Hunan Province Tumor Hospital6,000 enrolled1 locationNCT04322890
Recruiting
Phase 2
Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK
Lung AdenocarcinomaImmunotherapyALK Gene Mutation
Hunan Province Tumor Hospital78 enrolled1 locationNCT05266846
Recruiting
Phase 2
A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib
Non-small Cell Lung Cancer MetastaticALK Gene Mutation
Centro di Riferimento Oncologico - Aviano45 enrolled9 locationsNCT06378892
Recruiting
Phase 1Phase 2
Heat Therapy, Functional Capacity, and Vascular Health in Older Adults
Walking, DifficultyAging WellHyperemia
University of North Texas Health Science Center72 enrolled1 locationNCT05706181
Recruiting
Phase 2
Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC
ALK-positive Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials126 enrolled1 locationNCT06092086
Active
Phase 2
Cancer Molecular Screening and Therapeutics (MoST) Program and ASPiRATION subprogram, Addendum 14 – substudy 32: Alectinib
CancerALK gene alterations
University of Sydney16 enrolled9 locationsACTRN12621000312842
Completed
Phase 2
Proof of concept trial alternating lorlatinib with crizotinib in patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer
ALK-rearranged advanced non-small cell lung cancer
Royal North Shore Hospsital25 enrolled2 locationsACTRN12619000844145